We were unable to identify mutations in EMSY, BRIP, BARD1, and FOXM1 CNV in high-grade ovarian carcinoma as well as PTEN loss in clear cell carcinoma, LRPB1 loss and SOX17 amplification in uterine serous carcinoma (Table 2). This evidence concerns the gene BARD1 and clear cell adenocarcinoma.